Jeffrey Heier Sells 3,018 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Jeffrey Heier sold 3,018 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $8.20, for a total transaction of $24,747.60. Following the transaction, the insider directly owned 320,350 shares in the company, valued at approximately $2,626,870. The trade was a 0.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ocular Therapeutix Trading Down 1.5%

NASDAQ OCUL opened at $9.01 on Friday. The company’s fifty day simple moving average is $8.80 and its 200-day simple moving average is $10.22. Ocular Therapeutix, Inc. has a 52 week low of $6.23 and a 52 week high of $16.44. The company has a current ratio of 14.81, a quick ratio of 14.73 and a debt-to-equity ratio of 0.12. The stock has a market cap of $1.97 billion, a P/E ratio of -6.17 and a beta of 0.93.

Analyst Ratings Changes

OCUL has been the topic of a number of recent research reports. Needham & Company LLC reissued a “buy” rating and set a $18.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, May 5th. William Blair reissued an “outperform” rating on shares of Ocular Therapeutix in a research report on Monday, March 2nd. Chardan Capital reissued a “buy” rating and set a $21.00 target price on shares of Ocular Therapeutix in a research report on Wednesday, February 18th. Citigroup reissued an “outperform” rating on shares of Ocular Therapeutix in a research report on Tuesday, February 17th. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $30.00 target price on shares of Ocular Therapeutix in a research report on Wednesday, May 6th. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $23.78.

Institutional Trading of Ocular Therapeutix

Several institutional investors have recently added to or reduced their stakes in OCUL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Ocular Therapeutix by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 93,619 shares of the biopharmaceutical company’s stock valued at $686,000 after acquiring an additional 5,156 shares in the last quarter. Caxton Associates LLP acquired a new stake in Ocular Therapeutix in the first quarter valued at $248,000. Creative Planning raised its holdings in Ocular Therapeutix by 21.5% in the second quarter. Creative Planning now owns 21,410 shares of the biopharmaceutical company’s stock valued at $199,000 after acquiring an additional 3,791 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Ocular Therapeutix by 110.8% in the second quarter. JPMorgan Chase & Co. now owns 712,100 shares of the biopharmaceutical company’s stock valued at $6,608,000 after acquiring an additional 374,269 shares in the last quarter. Finally, Prudential Financial Inc. raised its holdings in Ocular Therapeutix by 57.9% in the second quarter. Prudential Financial Inc. now owns 18,700 shares of the biopharmaceutical company’s stock valued at $174,000 after acquiring an additional 6,855 shares in the last quarter. 59.21% of the stock is owned by institutional investors and hedge funds.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.